Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Stock-based Compensation (Tables)

Note 13 - Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2023

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

										*Weighted-*
										*Average*
						*Weighted-*				*Remaining*				*Aggregate*
		*Stock*				*Average*				*Contractual*				*Intrinsic*
		*Awards*				*Exercise Price*				*Life (Years)*				*Value*
Balance as of December 31, 2022			270			$	37.96
Options forfeited			—				—
Options cancelled			(9	)			77.08
Balance as of June 30, 2023			261			$	36.65				4.79			$	—
Vested and expected to vest at June 30, 2023			261			$	36.65				4.79			$	—
Exercisable as of June 30, 2023			257			$	37.06				4.77			$	—

Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]

						*Weighted-*
		*Number of*				*Average Grant*
		*Shares*				*Date Fair Value*
Unvested as of December 31, 2022			1,383			$	2.17
Granted			864				1.38
Vested			(677	)			1.92
Forfeited			(15	)			1.47
Unvested at June 30, 2023			1,555			$	1.85

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		*Three Months Ended June 30,*								*Six Months Ended June 30,*
		*2023*				*2022*				*2023*				*2022*
Sales and marketing		$	76			$	72			$	140			$	141
Research and development			131				104				213				183
General and administrative			307				406				585				757
		$	514			$	582			$	938			$	1,081